Studying genetic variations in cancer prognosis (and risk): A primer for clinicians

Oncologist

Volumn 14, Issue 7, 2009, Pages 657-666

  Savas, Sevtap ^a,b   Liu, Geoffrey ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Cancer predisposition; Candidate gene approach; Genome wide association studies; Low penetrance alleles; SNPs; Treatment response and prognosis

Indexed keywords

CANCER GENE THERAPY; CANCER RISK; CLINICAL PRACTICE; DISEASE PREDISPOSITION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SELECTION; GENETIC VARIABILITY; HUMAN; MEDICAL SPECIALIST; ONCOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SPLICEOSOME; STOP CODON; TREATMENT RESPONSE; UNTRANSLATED REGION;

GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; NEOPLASMS; PROGNOSIS; RISK FACTORS;

EID: 68549135136     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0042     Document Type: Review

References (74)

1. Chakravarti A. Population genetics-making sense out of sequence. Nat Genet 1999;21(1 suppl):56-60. (Pubitemid 29031494)
2. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996;273:1516-1517. (Pubitemid 26301653)
3. Efferth T, Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 2005;107:155-176.
4. Masson E, Zamboni WC. Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. Clin Pharmacokinet 1997;32:324-343. (Pubitemid 27160615)
5. Spitz MR, Wu X, Mills G. Integrative epidemiology: From risk assessment to outcome prediction. J Clin Oncol 2005;23:267-275. (Pubitemid 46206878)
6. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921. (Pubitemid 32165345)
7. Ionita-Laza I, Rogers AJ, Lange C et al. Genetic association analysis of copy-number variation (CNV) in human disease pathogenesis. Genomics 2009;93:22-26.
8. Miller RD, Phillips MS, Jo I et al. High-density single-nucleotide polymorphism maps of the human genome. Genomics 2005;86:117-126. (Pubitemid 40917219)
9. International HapMap Consortium; Frazer KA, Ballinger DG, Cox DR et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007;449:851-861.
10. The International Hap Map Consortium. The International Hap Map Project. Nature 2003;426:789-796. (Pubitemid 38056856)
11. Hu JJ, Mohrenweiser HW, Bell DA et al. Symposium overview: Genetic polymorphisms in DNA repair and cancer risk. Toxicol Appl Pharmacol 2002;185:64-73. (Pubitemid 35425698)
12. Temporini C, Calleri E, Massolini G et al. Integrated analytical strategies for the study of phosphorylation and glycosylation in proteins. Mass Spectrom Rev 2008;27:207-236. (Pubitemid 351547982)
13. Ng PC, Henikoff S. Accounting for human polymorphisms predicted to affect protein function. Genome Res 2002;12:436-446. (Pubitemid 34233019)
14. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001;11:863-874. (Pubitemid 32447869)
15. Sunyaev SR, LatheWCIII, Ramensky VE et al. SNP frequencies in human genes an excess of rare alleles and differing modes of selection. Trends Genet 2000;16:335-337.
16. Savas S, Ahmad MF, Shariff M et al. Candidate nsSNPs that can affect the functions and interactions of cell cycle proteins. Proteins 2005;58:697-705. (Pubitemid 40176041)
17. Savas S, Kim DY, Ahmad MF et al. Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomarkers Prev 2004;13:801-807. (Pubitemid 38737870)
18. Savas S, Taylor IW, Wrana JL et al. Functional nonsynonymous single nucleotide polymorphisms from the TGF-beta protein interaction network. Physiol Genomics 2007;29:109-117. (Pubitemid 46701992)
19. Xi T, Jones IM, Mohrenweiser HW. Many amino acid substitution variants identified in DNA repair genes during human population screenings are predicted to impact protein function. Genomics 2004;83:970-979. (Pubitemid 38726046)
20. Johnson MM, Houck J, Chen C. Screening for deleterious nonsynonymous single-nucleotide polymorphisms in genes involved in steroid hormone metabolism and response. Cancer Epidemiol Biomarkers Prev 2005;14: 1326-1329. (Pubitemid 40656491)
21. Wang D, Johnson AD, Papp AC et al. Multi drug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 2005;15:693-704. (Pubitemid 41345321)
22. Kimchi-Sarfaty C, Oh JM, Kim IW et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315:525-528.
23. Mamegano K, Kuroki K, Miyashita R et al. Association of LILRA2 (ILT1, LIR7) splice site polymorphism with systemic lupus erythematosus and microscopic polyangiitis. Genes Immun 2008;9:214-223. (Pubitemid 351584187)
24. Nielsen KB, Sørensen S, Cartegni L et al. Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating mutations: A synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer. Am J Hum Genet 2007;80:416-432. (Pubitemid 46310974)
25. Fairbrother WG, Holste D, Burge CB et al. Single nucleotide polymorphism- based validation of exonic splicing enhancers. PLoS Biol 2004;2: E268. (Pubitemid 39245248)
26. Fairbrother WG, Yeh RF, Sharp PA et al. Predictive identification of exonic splicing enhancers in human genes. Science 2002;297:1007-1013.
27. Pastinen T, Hudson TJ. Cis-acting regulatory variation in the human genome. Science 2004;306:647-650. (Pubitemid 39440905)
28. Whitney AR, Diehn M, Popper SJ et al. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci U S A 2003;100: 1896-1901. (Pubitemid 36254545)
29. Lo HS, Wang Z, Hu Y et al. Allelic variation in gene expression is common in the human genome. Genome Res 2003;13:1855-1862. (Pubitemid 36987191)
30. Stamatoyannopoulos JA. The genomics of gene expression. Genomics 2004;84:449-457.
31. Wittkopp PJ, Haerum BK, Clark AG. Evolutionary changes in cis and trans gene regulation. Nature 2004;430:85-88.
32. Kim SO, Jeong JY, Kim MR et al. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res 2008;14:3083-3088.
33. Audic Y, Hartley RS. Post-transcriptional regulation in cancer. Biol Cell 2004;96:479-498.
34. Katkoori VR, Jia X, Chatla C et al. Clinical significance of a novel single nucleotide polymorphism in the 5′ untranslated region of the rabphillin- 3A-like gene in colorectal adenocarcinoma. Front Biosci 2008;13:1050-1061. (Pubitemid 351594746)
35. Southam L, Rodriguez-Lopez J, Wilkins JM et al. An SNP in the 5′-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage. Hum Mol Genet 2007;16:2226-2232. (Pubitemid 47354904)
36. Cybulsky AV, Takano T, Papillon J et al. The 3′-untranslated region of the Ste20-like kinase SLK regulates SLK expression. Am J Physiol Renal Physiol 2007;292:F845-F852. (Pubitemid 46220554)
37. Espel E. The role of the AU-rich elements of mRNAs in controlling translation. Semin Cell Dev Biol 2005;16:59-67. (Pubitemid 40136538)
38. Yu Z, Li Z, Jolicoeur N et al. Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res 2007;35:4535-4541. (Pubitemid 47244604)
39. Mishra PJ, Humeniuk R, Mishra PJ et al.AmiR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci U S A 2007;104:13513-13518. (Pubitemid 47293976)
40. Landi D, Gemignani F, Barale R et al. A catalog of polymorphisms falling in microRNA-binding regions of cancer genes. DNA Cell Biol 2008;27: 35-43.
41. Landi D, Gemignani F, Naccarati A et al. Polymorphisms within micro- RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis 2008;29:579-584.
42. Savas S, Tuzmen S, Ozcelik H. Human SNPs resulting in premature stop codons and protein truncation. Hum Genomics 2006;2:274-286.
43. Kittles RA, Baffoe-Bonnie AB, Moses TY et al. A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J Med Genet 2006;43:507-511.
44. Han A, Kim WY, Park SM. SNP2NMD: A database of human single nucleotide polymorphisms causing nonsense-mediated mRNA decay. Bioinformatics 2007;23:397-399. (Pubitemid 46323171)
45. Oldenburg RA, Meijers-Heijboer H, Cornelisse CJ et al. Genetic susceptibility for breast cancer: How many more genes to be found? Crit Rev Oncol Hematol 2007;63:125-149. (Pubitemid 46990913)
46. Gold B, Kirchhoff T, Stefanov S et al. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A 2008;105:4340-4345. (Pubitemid 351754382)
47. Hunter DJ, Kraft P, Jacobs KB et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39:870-874. (Pubitemid 47014500)
48. Hung RJ, McKay JD, Gaborieau V et al. Asusceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008;452:633-637.
49. Thomas G, Jacobs KB, Yeager M et al. Multiple loci identified in a genome- wide association study of prostate cancer. Nat Genet 2008;40:310-315. (Pubitemid 351311773)
50. Tomlinson IP, Webb E, Carvajal-Carmona L et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet 2008;40:623-630. (Pubitemid 351601204)
51. Pittman AM, Webb E, Carvajal-Carmona L et al. Refinement of the basis and impact of common 11q23.1 variation to the risk of developing colorectal cancer. Hum Mol Genet 2008;17:3720-3727.
52. Guengerich FP. Metabolism of chemical carcinogens. Carcinogenesis 2000;21:345-351.
53. Belle DJ, Singh H. Genetic factors in drug metabolism. Am Fam Physician 2008;77:1553-1560.
54. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991;51:3075-3079.
55. Gossage L, Madhusudan S. Cancer pharmacogenomics: Role of DNA repair genetic polymorphisms in individualizing cancer therapy. Mol Diagn Ther 2007;11:361-380. (Pubitemid 350274404)
56. Todd R, Wong DT. Epidermal growth factor receptor (EGFR) biology and human oral cancer. Histol Histopathol 1999;14:491-500. (Pubitemid 29159018)
57. Zhu ZZ, Wang AZ, Jia HR et al. Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol 2007;37:385-390. (Pubitemid 47248959)
58. Wang AZ, Zhu ZZ, Cong WM. [Association of TP53 gene polymorphisms with genetic susceptibility to liver metastases of colorectal cancer.] Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2008;25:168 -171. In Chinese.
59. Wijnhoven BP, Dinjens WN, Pignatelli M. E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 2000;87:992-1005. (Pubitemid 30496847)
60. Seal S, Thompson D, Renwick A et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006;38:1239-1241. (Pubitemid 44646283)
61. Karppinen SM, Barkardottir RB, Backenhorn K et al. Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: Enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies. J Med Genet 2006;43:856-862. (Pubitemid 44787111)
62. Houlston RS, Tomlinson IP. Detecting low penetrance genes in cancer: The way ahead. J Med Genet 2000;37:161-167. (Pubitemid 30245908)
63. Forbes SA, Bhamra G, Bamford S et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet 2008;Chapter 10:Unit 10.11.
64. Greenman C, Stephens P, Smith R et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-158. (Pubitemid 46398669)
65. Torkamani A, Schork NJ. Prediction of cancer driver mutations in protein kinases. Cancer Res 2008;68:1675-1682.
66. Elwood JM, Pearson JC, Skippen DH et al. Alcohol, smoking, social and occupational factors in the aetiology of cancer of the oral cavity, pharynx and larynx. Int J Cancer 1984;34:603-612.
67. Okobia MN, Bunker CH. Epidemiological risk factors for breast cancer-a review. Niger J Clin Pract 2005;8:35-42.
68. Ziegler A, Konig IR, Thompson JR. Biostatistical aspects of genome-wide association studies. Biom J 2008;50:8-28.
69. Motsinger AA, Ritchie MD, Dobrin SE. Clinical applications of whole genome association studies: Future applications at the bedside. Expert Rev Mol Diagn 2006;6:551-565.
70. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995;57:289-300.
71. Rice TK, Schork NJ, Rao DC. Methods for handling multiple testing. Adv Genet 2008;60:293-308.
72. McCarroll SA. Extending genome-wide association studies to copy-number variation. Hum Mol Genet 2008;17:R135-R142.
73. Zogopoulos G, Ha KC, Naqib F et al. Germ-line DNA copy number variation frequencies in a large North American population. Hum Genet 2007; 122:345-353. (Pubitemid 47616542)
74. Shlien A, Tabori U, Marshall CR et al. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci U S A 2008;105:11264-11269.